Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2020-10-23 DOI:10.1021/acscombsci.0c00099

Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Farid Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Mahshad Kalantari, Shima Tavakol, Reza Mohammadinejad, Masoud Najafi*, Franklin R. Tay, Pooyan Makvandi*

{"title":"Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy","authors":"Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Farid Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Mahshad Kalantari, Shima Tavakol, Reza Mohammadinejad, Masoud Najafi*, Franklin R. Tay, Pooyan Makvandi*","doi":"10.1021/acscombsci.0c00099","DOIUrl":null,"url":null,"abstract":"<p >Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1021/acscombsci.0c00099","citationCount":"61","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acscombsci.0c00099","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 61

Abstract

Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于纳米载体的天然化合物/siRNA共递送在癌症治疗中的进展

化疗使用天然化合物，如白藜芦醇、姜黄素、紫杉醇、多西紫杉醇、依托泊苷、阿霉素和喜树碱，在癌症治疗中很重要，因为这些化合物具有突出的治疗活性和多靶向能力。然而，天然化合物较差的溶解度和生物利用度限制了它们在癌症治疗中的疗效。为了克服这一障碍，纳米载体被设计用来提高上述化合物的抗肿瘤活性。然而，癌症治疗仍然是一个挑战，需要新的策略。众所周知，天然产物和基因疗法的结合优于单一疗法。多种治疗药物/小干扰RNA (small interfering RNA, siRNA)作为一种强有力的基因编辑工具在癌症治疗中可以最大限度地发挥对肿瘤细胞的协同作用。本文重点介绍了利用纳米载体实现天然化合物/siRNA的共递送，为今后的研究提供了背景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊